Platelet Transfusion Guidelines in Dengue Patients

Indications for Transfusion

• For active bleeding, a target platelet count of ≥50,000/mm³ is advised, as recommended by the American College of Critical Care Medicine and the American Society of Clinical Oncology 1, 2
• The American Society of Clinical Oncology recommends maintaining platelet counts at 40,000-50,000/mm³ for patients requiring invasive procedures or surgery 2
• For central venous catheter placement, the American College of Physicians recommends transfusing if platelet count is <20,000/mm³ 3, 4
• For lumbar puncture, the American College of Physicians recommends transfusing if platelet count is <50,000/mm³ 3, 5

Special Considerations

• The American College of Critical Care Medicine suggests considering platelet transfusion in patients with platelet counts <20,000/mm³ and additional risk factors for bleeding, such as advanced age 4, hypertension 1, peptic ulcer disease 1, anticoagulant use 1, or recent trauma or surgery 2
• The American Society of Clinical Oncology recommends obtaining a post-transfusion platelet count to confirm that the desired platelet count has been reached 2

Practical Approach to Platelet Transfusion

• The American College of Critical Care Medicine and the American Society of Clinical Oncology recommend assessing for active bleeding and transfusing platelets to maintain count ≥50,000/mm³ if present and significant 1, 2
• The American Society of Clinical Oncology recommends evaluating the need for invasive procedures and maintaining platelets at 40,000-50,000/mm³ for major procedures 2
• The American College of Physicians recommends transfusing for minor procedures based on procedure type, with thresholds varying from 20,000-50,000/mm³ 3, 4

Platelet Transfusion Protocol in Dengue

Supportive Care Protocol

• The American Society of Clinical Oncology recommends adequate fluid therapy for dengue patients with thrombocytopenia without bleeding 6
• The American Society of Clinical Oncology suggests fever and pain management (avoid NSAIDs/aspirin) for dengue patients with thrombocytopenia without bleeding 7
• Serial platelet count monitoring is recommended for dengue patients with thrombocytopenia without bleeding 8

Transfusion Dosing When Indicated

• The American Society of Clinical Oncology recommends using 4 units of pooled platelet concentrates or one apheresis unit when transfusion is necessary 6
• Having additional units available if intraoperative/postoperative bleeding occurs is suggested 9

Common Pitfalls to Avoid

• The American Society of Clinical Oncology guidelines for cancer patients (10,000/μL threshold for prophylaxis) do not apply to dengue, where thrombocytopenia results from increased platelet destruction rather than impaired marrow production 8
• Prophylactic transfusion is relatively contraindicated in conditions with increased platelet destruction 8, 7

Indications for Platelet Transfusion in Dengue

Evidence and Guidelines

• The American College of Physicians and other medical societies recommend against prophylactic platelet transfusion in dengue patients with severe thrombocytopenia without bleeding, as it does not reduce clinical bleeding and is associated with more adverse events, according to the Journal of Clinical Oncology 10

Transfusion Thresholds

• The World Health Organization suggests that platelet transfusion may be considered in patients with platelets <20,000/μL and concomitant coagulopathy, although clinical judgment is essential, as stated in guidelines similar to those from the Journal of Clinical Oncology 10

Platelet Transfusion Criteria in Dengue Fever

Evidence-Based Approach to Platelet Transfusion in Dengue

• The American Society of Clinical Oncology recommends that prophylactic platelet transfusion is contraindicated in dengue patients with thrombocytopenia due to increased platelet destruction rather than impaired marrow production, which is a critical distinction from cancer patients with bone marrow failure 11, 12
• The World Health Organization suggests that the pathophysiology of dengue is fundamentally different from cancer/leukemia, causing peripheral platelet destruction and consumption, not marrow failure, and therefore cancer guidelines should not be applied to dengue patients 12

Platelet Transfusion Guidelines in Dengue Patients

Introduction to Dengue-Related Thrombocytopenia

• Prophylactic platelet transfusion is relatively contraindicated in conditions with increased platelet destruction, such as dengue, as opposed to hypoproliferative thrombocytopenia where it is standard practice, according to the American Society of Clinical Oncology 13

Evidence-Based Transfusion Thresholds

• There is no established benefit for prophylactic platelet transfusion in dengue patients with platelets ≤20,000/μL, with a bleeding rate of 21% in the transfusion group vs 26% in the supportive care group, as per the World Health Organization guidelines 13
• The American College of Physicians recommends targeting a platelet count ≥50,000/μL for patients with active bleeding requiring intervention, with a strength of evidence rated as moderate 13

Transfusion Management

• The International Society of Thrombosis and Haemostasis suggests using 4 units of pooled platelet concentrates or one apheresis unit when transfusion is necessary, with a post-transfusion platelet count to confirm adequate levels have been achieved 13

Platelet Transfusion Guidelines in Dengue Patients

Introduction to Dengue Transfusion Guidelines

• The American Society of Clinical Oncology recommends a prophylactic platelet transfusion threshold of 10,000/μL for hypoproliferative thrombocytopenia from chemotherapy, but this guideline is not applicable to dengue patients due to differences in pathophysiology 14

Indications for Platelet Transfusion in Dengue

• Platelet transfusion is indicated in dengue patients with active significant bleeding, with a target platelet count of ≥50,000/μL for any clinically significant hemorrhage requiring intervention 14
• The World Health Organization suggests that platelet transfusion may be considered in dengue patients undergoing invasive procedures, with a target platelet count of ≥50,000/μL for major surgery or lumbar puncture, ≥40,000-50,000/μL for most major invasive procedures, and ≥20,000/μL for central venous catheter placement 14
• Platelet transfusion may be considered in high-risk clinical scenarios, such as concomitant coagulopathy, with a threshold of <20,000/μL 14

Platelet Transfusion Thresholds in Dengue Patients

Active Significant Bleeding

• For dengue patients with clinically significant hemorrhage requiring intervention, aim for a platelet count ≥ 50,000/µL and administer four units of pooled platelet concentrates or one apheresis unit. Post‑transfusion platelet count should be obtained to confirm adequacy. Evidence level: moderate (clinical study). 15

Invasive Procedures

• Major surgery or lumbar puncture – target platelet count ≥ 50,000/µL before the procedure. Evidence level: moderate. 16
• Most other major invasive procedures – target platelet count 40,000–50,000/µL. Evidence level: moderate. 15
• Central venous catheter placement – target platelet count ≥ 20,000/µL. Evidence level: moderate. 17

Clinical Decision Algorithm for Planned Procedures

• When a dengue patient is scheduled for an invasive procedure, transfuse platelets to achieve the procedure‑specific threshold (20,000–50,000/µL depending on the intervention). Evidence level: moderate. 15

Transfusion Monitoring and Dosing

• After any platelet transfusion, obtain a post‑transfusion platelet count to verify that the target level has been reached. Evidence level: moderate. 15